MedTrace Logo

Study of Fat Malabsorption by Lipiblock Versus Xenical

NCT01170806 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-01-31

No results posted yet for this study

Summary

Obesity is a chronic condition with fat-rich diets playing a major role in its etiology. Pharmacological therapy has been proposed for weight loss and maintenance. This study aims to study the intestinal lipase blockade by partial inhibition of fat absorption after treatment with two commercials formulations of Orlistat.

Conditions

Interventions

DRUG

Orlistat

Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy

Sponsors & Collaborators

  • Germed Pharma

    collaborator INDUSTRY

  • University of Campinas, Brazil

    lead OTHER

Principal Investigators

  • Bruno Geloneze, MD PhD · University of Campinas (UNICAMP)

  • Sabrina Nagassaki, PharmD PhD · University of Campinas (UNICAMP)

  • Christiane Stabe, MSc · University of Campinas (UNICAMP)

  • Daniela Tezoto · University of Campinas (UNICAMP)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-03-31
Completion
2010-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01170806 on ClinicalTrials.gov